
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5930831/publications.pdf Version: 2024-02-01



ΤΗΟΜΛΟ ΚΑΊ/ΗΝΕ

#	Article	IF	CITATIONS
1	Secondary malignant neoplasms after bone and soft tissue sarcomas in children, adolescents, and young adults. Cancer, 2022, 128, 1787-1800.	4.1	8
2	Registries in immune thrombocytopenia (ITP) in Europe: the European Research Consortium on ITP (<scp>ERCI</scp>) network. British Journal of Haematology, 2022, 197, 633-638.	2.5	2
3	High-Dose Treosulfan and Melphalan as Consolidation Therapy Versus Standard Therapy for High-Risk (Metastatic) Ewing Sarcoma. Journal of Clinical Oncology, 2022, 40, 2307-2320.	1.6	24
4	Value of adjuvant radiotherapy in patients with localized Ewing sarcoma at the extremities: Report from the Ewing 2008 trial Journal of Clinical Oncology, 2022, 40, 11531-11531.	1.6	0
5	Phase III assessment of topotecan and cyclophosphamide and high-dose ifosfamide in rEECur: An international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma (RR-ES) Journal of Clinical Oncology, 2022, 40, LBA2-LBA2.	1.6	11
6	Misdiagnosed thrombocytopenia in children and adolescents: analysis of the Pediatric and Adult Registry on Chronic ITP. Blood Advances, 2021, 5, 1617-1626.	5.2	11
7	Association of treatment delays with an unfavorable outcome in patients with localized Ewing sarcoma: A retrospective analysis of data from the GPOH Euro-E.W.I.N.G.99 trial Journal of Clinical Oncology, 2021, 39, 11502-11502.	1.6	3
8	The EHA Research Roadmap: Platelet Disorders. HemaSphere, 2021, 5, e601.	2.7	3
9	Understanding Immune Thrombocytopenia: Looking Out of the Box. Frontiers in Medicine, 2021, 8, 613192.	2.6	12
10	Outcome in dedifferentiated chondrosarcoma for patients treated with multimodal therapy: Results from the EUROpean Bone Over 40 Sarcoma Study. European Journal of Cancer, 2021, 151, 150-158.	2.8	19
11	Romiplostim in children with newly diagnosed or persistent primary immune thrombocytopenia. Annals of Hematology, 2021, 100, 2143-2154.	1.8	7
12	Immunomodulation with Romiplostim in Young Adult Primary Immune Thrombocytopenia (ITP) As Second-Line Strategy (iROM-study). Blood, 2021, 138, 3149-3149.	1.4	1
13	Adolescents and Young Adults with Immune Thrombocytopenia (ITP): A Project of the Carmen-France and Parc-ITP Registry. Blood, 2021, 138, 2079-2079.	1.4	1
14	Immune Thrombocytopenia (ITP): Current Limitations in Patient Management. Medicina (Lithuania), 2020, 56, 667.	2.0	20
15	Pathological Fracture and Prognosis of High-Grade Osteosarcoma of the Extremities: An Analysis of 2,847 Consecutive Cooperative Osteosarcoma Study Group (COSS) Patients. Journal of Clinical Oncology, 2020, 38, 823-833.	1.6	45
16	Long-term outcomes after splenectomy in children with immune thrombocytopenia: an update on the registry data from the Intercontinental Cooperative ITP Study Group. Haematologica, 2020, 105, 2682-2685.	3.5	8
17	Efficacy of add-on treosulfan and melphalan high-dose therapy in patients with high-risk metastatic Ewing sarcoma: Report from the International Ewing 2008R3 trial Journal of Clinical Oncology, 2020, 38, 11501-11501.	1.6	6
18	Results of the second interim assessment of rEECur, an international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma (RR-ES) Journal of Clinical Oncology, 2020, 38, 11502-11502.	1.6	34

#	Article	IF	CITATIONS
19	Efficacy of maintenance therapy with zoledronic acid in patients with localized Ewing sarcoma: Report from the international Ewing 2008 trial Journal of Clinical Oncology, 2020, 38, 11523-11523.	1.6	8
20	Correlation of response with progression-free (PFS) and overall (OS) survival in relapsed/refractory Ewing sarcoma (RR-ES): Results from the rEECur trial Journal of Clinical Oncology, 2020, 38, 11524-11524.	1.6	1
21	High-Dose Chemotherapy Compared With Standard Chemotherapy and Lung Radiation in Ewing Sarcoma With Pulmonary Metastases: Results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008. Journal of Clinical Oncology, 2019, 37, 3192-3202.	1.6	84
22	Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. European Journal of Cancer, 2019, 109, 36-50.	2.8	354
23	Communication Skills Training for Professionals Working with Adolescent Patients with Cancer Based on Participants' Needs: A Pilot. Journal of Adolescent and Young Adult Oncology, 2019, 8, 354-362.	1.3	8
24	Immunomodulation in Primary Immune Thrombocytopenia: A Possible Role of the Fc Fragment of Romiplostim?. Frontiers in Immunology, 2019, 10, 1196.	4.8	17
25	The relation of radiological tumor volume response to histological response and outcome in patients with localized Ewing Sarcoma. Cancer Medicine, 2019, 8, 1086-1094.	2.8	14
26	American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Advances, 2019, 3, 3829-3866.	5.2	684
27	Results of the first interim assessment of rEECur, an international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma Journal of Clinical Oncology, 2019, 37, 11007-11007.	1.6	20
28	Recurrence of Ewing sarcoma: Is detection by imaging followâ€up protocol associated with survival advantage?. Pediatric Blood and Cancer, 2018, 65, e27011.	1.5	22
29	A comparative prospective observational study of children and adults with immune thrombocytopenia: 2â€year followâ€up. American Journal of Hematology, 2018, 93, 751-759.	4.1	38
30	Palliative care in Swiss pediatric oncology settings: a retrospective analysis of medical records. Supportive Care in Cancer, 2018, 26, 2707-2715.	2.2	10
31	Advances in chemical pharmacotherapy for the treatment of pediatric immune thrombocytopenia. Expert Opinion on Pharmacotherapy, 2018, 19, 667-676.	1.8	2
32	Predictors of remission in children with newly diagnosed immune thrombocytopenia: Data from the Intercontinental Cooperative ITP Study Group Registry II participants. Pediatric Blood and Cancer, 2018, 65, e26736.	1.5	51
33	Immune Thrombocytopenia - Current Diagnostics and Therapy: Recommendations of a Joint Working Group of DGHO, ÖGHO, SGH, GPOH, and DGTI. Oncology Research and Treatment, 2018, 41, 1-30.	1.2	72
34	Immunthrombozytopenie - aktuelle Diagnostik und Therapie: Empfehlungen einer gemeinsamen Arbeitsgruppe der DGHO, ÖGHO, SGH, GPOH und DGTI. Oncology Research and Treatment, 2018, 41, 5-36.	1.2	12
35	Burden of treatment in the face of childhood cancer: A quantitative study using medical records of deceased children. European Journal of Cancer Care, 2018, 27, e12879.	1.5	7
36	Registries in Immune Thrombocytopenia: The History of theÂIntercontinental Cooperative ITP Study		1

nbocytopenia: T ooperative 36 Group. , 2018, , 277-287. i y i

#	Article	IF	CITATIONS
37	Analysis of Children with Secondary ITP an Observational Study of Children of the Parc-ITP Registry of the Intercontinental Cooperative ITP Study Group (ICIS). Blood, 2018, 132, 1146-1146.	1.4	8
38	Parents' and Physicians' Perceptions of Children's Participation in Decision-making in Paediatric Oncology: A Quantitative Study. Journal of Bioethical Inquiry, 2017, 14, 555-565.	1.5	13
39	Decision making in pediatric oncology: Views of parents and physicians in two European countries. AJOB Empirical Bioethics, 2017, 8, 21-31.	1.6	20
40	Diagnosis and management of immune thrombocytopenia in childhood. Hamostaseologie, 2017, 37, 36-44.	1.9	39
41	Intracranial Hemorrhage as the First Manifestation of Severe Congenital Factor X Deficiency in a 20â€Monthâ€Old Male: Case Report and Review of the Literature. Pediatric Blood and Cancer, 2016, 63, 1300-1304.	1.5	3
42	Cancer care in Romania: challenges and pitfalls of children's and adolescents' multifaceted involvement. Journal of Medical Ethics, 2016, 42, 757-761.	1.8	7
43	D03-B Decision-making in Pediatric Oncology: Prospective Survey Study with Parents and Physicians. Journal of Pain and Symptom Management, 2016, 52, e31.	1.2	0
44	Thrombopoietin receptor agonists: a new immune modulatory strategy in immune thrombocytopenia?. Seminars in Hematology, 2016, 53, S31-S34.	3.4	36
45	Putting patient participation into practice in pediatrics—results from a qualitative study in pediatric oncology. European Journal of Pediatrics, 2016, 175, 1147-1155.	2.7	32
46	Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. Lancet Oncology, The, 2016, 17, 1396-1408.	10.7	356
47	5th Intercontinental Cooperative ITP Study Group (ICIS) expert meeting in Flüeli-Ranft, Switzerland, September 2015. Seminars in Hematology, 2016, 53, S1.	3.4	2
48	Kompendium KinderhÃ m atologie. , 2016, , .		1
49	A Comparative Prospective Observational Study of Children and Adults with Immune Thrombocytopenia: 2-Year Follow-up. Blood, 2016, 128, 3741-3741.	1.4	3
50	Parents' and patients' experiences with paediatric oncology care in Switzerland – satisfaction and some hurdles. Swiss Medical Weekly, 2016, 146, w14309.	1.6	15
51	Impact of gender on efficacy and acute toxicity of alkylating agent -based chemotherapy in Ewing sarcoma: Secondary analysis of the Euro-Ewing99-R1 trial. European Journal of Cancer, 2015, 51, 2453-2464.	2.8	21
52	Fanconi Anemia. Journal of Pediatric Hematology/Oncology, 2015, 37, 335-343.	0.6	15
53	Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial. Iournal of Clinical Oncology, 2015, 33, 2279-2287.	1.6	329
54	Treatment of Pediatric Primary Immune Thrombocytopenia With Thrombopoietin Receptor Agonists.	3.4	8

Seminars in Hematology, 2015, 52, 25-30.

THOMAS KüHNE

#	Article	IF	CITATIONS
55	Transient myeloproliferative disorder in neonates without Down syndrome: case report and review. European Journal of Haematology, 2015, 94, 456-462.	2.2	14
56	Event-free survival and overall survival in 2,253 patients with osteosarcoma registered to EURAMOS-1 Journal of Clinical Oncology, 2015, 33, 10512-10512.	1.6	4
57	A Prospective Multicenter Study of Microbiologically Defined Infections in Pediatric Cancer Patients With Fever and Neutropenia. Pediatric Infectious Disease Journal, 2014, 33, e219-e225.	2.0	32
58	Morphologic and GATA1 sequencing analysis of hematopoiesis in fetuses with trisomy 21. Human Pathology, 2014, 45, 1003-1009.	2.0	12
59	Forty years of haematopoietic stem cell transplantation: a review of the Basel experience. Swiss Medical Weekly, 2014, 144, w13928.	1.6	7
60	Update on the intercontinental cooperative ITP study group (ICIS) and on the pediatric and adult registry on chronic ITP (PARC ITP). Pediatric Blood and Cancer, 2013, 60, S15-8.	1.5	14
61	Chronic Immune Thrombocytopenia in Children: Who Needs Splenectomy?. Seminars in Hematology, 2013, 50, S58-S62.	3.4	14
62	4th Intercontinental Cooperative ITP Study Group (ICIS) Expert Meeting in Montreux, Switzerland, September 2012. Seminars in Hematology, 2013, 50, S1-S2.	3.4	1
63	Benefits and Adverse Events in Younger Versus Older Patients Receiving Neoadjuvant Chemotherapy for Osteosarcoma: Findings From a Meta-Analysis. Journal of Clinical Oncology, 2013, 31, 2303-2312.	1.6	161
64	Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group. Blood, 2013, 121, 2596-2606.	1.4	179
65	Bleeding manifestations and management of children with persistent and chronic immune thrombocytopenia: data from the Intercontinental Cooperative ITP Study Group (ICIS). Blood, 2013, 121, 4457-4462.	1.4	87
66	MAP plus maintenance pegylated interferon α-2b (MAPIfn) versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: First results of the EURAMOS-1 "good response〕randomization Journal of Clinical Oncology, 2013, 31, LBA10504-LBA10504.	1.6	14
67	MAP plus maintenance pegylated interferon α-2b (MAP-IFN) versus MAP alone in patients (pts) with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: First results of the EURAMOS-1 good response randomization Journal of Clinical Oncology, 2013, 31, LBA10504-LBA10504.	1.6	4
68	Firstâ€day stepâ€down to oral outpatient treatment versus continued standard treatment in children with cancer and lowâ€risk fever in neutropenia. A randomized controlled trial within the multicenter SPOG 2003 FN study. Pediatric Blood and Cancer, 2012, 59, 423-430.	1.5	36
69	EURAMOS-1 study: Recruitment, characteristics, and initial treatment of more than 2,000 patients (pts) with high-grade osteosarcoma Journal of Clinical Oncology, 2012, 30, 10081-10081.	1.6	3
70	Predicting Bacteremia in Children With Cancer and Fever in Chemotherapy-induced Neutropenia. Pediatric Infectious Disease Journal, 2011, 30, e114-e119.	2.0	60
71	Reply to K.G.E. Miedema et al. Journal of Clinical Oncology, 2011, 29, e185-e185.	1.6	1
72	Newly diagnosed immune thrombocytopenia in children and adults: a comparative prospective observational registry of the Intercontinental Cooperative Immune Thrombocytopenia Study Group. Haematologica, 2011, 96, 1831-1837.	3.5	118

#	Article	IF	CITATIONS
73	Eltrombopag: an update on the novel, non-peptide thrombopoietin receptor agonist for the treatment of immune thrombocytopenia. Annals of Hematology, 2010, 89, 67-74.	1.8	48
74	Sperm analysis of patients after successful treatment of childhood acute lymphoblastic leukemia with chemotherapy. Pediatric Blood and Cancer, 2010, 55, 208-210.	1.5	13
75	Predicting Adverse Events in Children With Fever and Chemotherapy-Induced Neutropenia: The Prospective Multicenter SPOG 2003 FN Study. Journal of Clinical Oncology, 2010, 28, 2008-2014.	1.6	140
76	A New Stable α Chain Variant: Hb Basel [α14(A12)Trp→Leu (α1)]. Hemoglobin, 2010, 34, 327-331.	0.8	1
77	Second and Subsequent Recurrences of Osteosarcoma: Presentation, Treatment, and Outcomes of 249 Consecutive Cooperative Osteosarcoma Study Group Patients. Journal of Clinical Oncology, 2009, 27, 557-565.	1.6	210
78	Non-classical karyotypic features in relapsed childhood B-cell precursor acute lymphoblastic leukemia. Cancer Genetics and Cytogenetics, 2009, 189, 29-36.	1.0	5
79	Possible lower rate of chronic ITP after IVIG for acute childhood ITP an analysis from registry I of the Intercontinental Cooperative ITP Study Group (ICIS). British Journal of Haematology, 2009, 146, 180-184.	2.5	49
80	Osteosarcoma: The COSS Experience. Cancer Treatment and Research, 2009, 152, 289-308.	0.5	166
81	Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood, 2009, 113, 2386-2393.	1.4	2,128
82	New GATA1 mutation in codon 2 leads to the earliest known premature stop codon in transient myeloproliferative disorder. Blood, 2009, 114, 3717-3718.	1.4	5
83	Bleeding Manifestations and Management of Children with Persistent and Chronic Immune Thrombocytopenia (ITP): Data From the Intercontinental Cooperative ITP Study Group Blood, 2009, 114, 1315-1315.	1.4	2
84	Evans syndrome and idiopathic thrombocytopenic purpura in families: Consider autoimmune lymphoproliferative disease. Pediatric Blood and Cancer, 2008, 50, 1295-1296.	1.5	5
85	Ghost in the tree. Lancet, The, 2008, 372, 1570.	13.7	2
86	Severe hemorrhage in children with newly diagnosed immune thrombocytopenic purpura. Blood, 2008, 112, 4003-4008.	1.4	171
87	Helicobacter pylori in Children With Chronic Idiopathic Thrombocytopenic Purpura: Are the Obstacles in the Way Typical in Pediatric Hematology?. Journal of Pediatric Hematology/Oncology, 2008, 30, 2-3.	0.6	6
88	Neutrality, Compensation, and Negative Selection during Evolution of B-Cell Development Transcriptomes. Molecular Biology and Evolution, 2007, 24, 2610-2618.	8.9	7
89	Characterization of high-hyperdiploidy in childhood acute lymphoblastic leukemia with gain of a single chromosome 21. Leukemia and Lymphoma, 2007, 48, 2457-2460.	1.3	2
90	Loss of i(8)(q10) at relapse in two cases of childhood acute myeloid leukaemia. Leukemia and Lymphoma, 2007, 48, 1045-1047.	1.3	1

THOMAS KüHNE

#	Article	IF	CITATIONS
91	Precursor B lymphoblastic leukemia 32 months after local therapy for a primary extramedullary myeloid cell tumor. Pediatric Blood and Cancer, 2007, 49, 1039-1046.	1.5	2
92	Splenectomy in children with idiopathic thrombocytopenic purpura: A prospective study of 134 children from the Intercontinental Childhood ITP Study Group. Pediatric Blood and Cancer, 2007, 49, 829-834.	1.5	98
93	The prognostic significance of cytogenetic aberrations in childhood acute myeloid leukaemia. A study of the Swiss Paediatric Oncology Group (SPOG). European Journal of Haematology, 2007, 78, 468-476.	2.2	39
94	Real-time broad-range PCR versus blood culture. A prospective pilot study in pediatric cancer patients with fever and neutropenia. Supportive Care in Cancer, 2007, 15, 637-641.	2.2	12
95	Dose intensity of chemotherapy for osteosarcoma and outcome in the Cooperative Osteosarcoma Study Group (COSS) trials. Pediatric Blood and Cancer, 2006, 47, 42-50.	1.5	72
96	Idiopathic thrombocytopenic purpura in childhood: Controversies and solutions. Pediatric Blood and Cancer, 2006, 47, 650-652.	1.5	16
97	2nd ICIS Expert Meeting 2006 on critical issues and future development of research in ITP. Pediatric Blood and Cancer, 2006, 47, 649-649.	1.5	4
98	Idiopathic thrombocytopenic purpura (ITP): Is there a genetic predisposition?. Pediatric Blood and Cancer, 2006, 47, 678-680.	1.5	32
99	Allogeneic haematopoietic stem cell transplantation in relapsed or refractory anaplastic large cell lymphoma of children and adolescents - a Berlin-Frankfurt-Munster group report. British Journal of Haematology, 2006, 133, 176-182.	2.5	119
100	Pediatric Clinical Research in Benign Hematology. Journal of Pediatric Hematology/Oncology, 2005, 27, 637-638.	0.6	2
101	Threeâ€year recurrenceâ€free survival in a patient with recurrent medulloblastoma after resection, highâ€dose chemotherapy, and intrathecal Yttriumâ€90â€labeled DOTA ⁰ â€Dâ€Phe ¹ â€Tyr ³ â€octreotide radiopeptide brachytherapy. Cance 2005, 103, 869-873.	r, ^{4.1}	26
102	Quality-adjusted survival analysis shows differences in outcome after immunosuppression or bone marrow transplantation in aplastic anemia. Annals of Hematology, 2005, 84, 47-55.	1.8	48
103	Characterization of karyotypic events and evolution in neuroblastoma. Pediatric Blood and Cancer, 2005, 44, 147-157.	1.5	20
104	Overexpression of Human Dickkopf-1, an Antagonist of wingless/WNT Signaling, in Human Hepatoblastomas and Wilms' Tumors. Laboratory Investigation, 2003, 83, 429-434.	3.7	134
105	A prospective comparative study of 2540 infants and children with newly diagnosed idiopathic thrombocytopenic purpura (ITP) from the intercontinental childhood ITP study group. Journal of Pediatrics, 2003, 143, 605-608.	1.8	249
106	Idiopathic thrombocytopenic purpura of childhood: A problem-oriented review of the management. Transfusion and Apheresis Science, 2003, 28, 243-248.	1.0	6
107	New Developments in Idiopathic Thrombocytopenic Purpura (ITP): Cooperative, Prospective Studies by the Intercontinental Childhood ITP Study Group. Journal of Pediatric Hematology/Oncology, 2003, 25, S74-S76.	0.6	8
108	Overview of the State of the Art Expert Meeting of the Intercontinental Childhood ITP Study Group (ICIS). Journal of Pediatric Hematology/Oncology, 2003, 25, S1-S6.	0.6	6

THOMAS KüHNE

#	Article	IF	CITATIONS
109	Self-Reported Initial Management of Childhood Idiopathic Thrombocytopenic Purpura: Results of a Survey of Members of the American Society of Pediatric Hematology/Oncology, 2001. Journal of Pediatric Hematology/Oncology, 2003, 25, 130-133.	0.6	52
110	Investigation and Management of Newly Diagnosed Childhood Idiopathic Thrombocytopenic Purpura: Problems and Proposed Solutions. Journal of Pediatric Hematology/Oncology, 2003, 25, S24-S27.	0.6	8
111	Congenital Self-Healing Langerhans Cell Histiocytosis With Atrophic Recovery of the Skin: Clinical Correlation of an Immunologic Phenomenon. Journal of Pediatric Hematology/Oncology, 2003, 25, 270-273.	0.6	11
112	Co-occurrence of neuroblastoma and nephroblastoma in an infant with Fanconi's anemia. Human Pathology, 2002, 33, 1047-1051.	2.0	20
113	Historical Aspects and Present Knowledge of Idiopathic Thrombocytopenic Purpura. British Journal of Haematology, 2002, 119, 894-900.	2.5	33
114	Newly diagnosed idiopathic thrombocytopenic purpura in childhood: an observational study. Lancet, The, 2001, 358, 2122-2125.	13.7	231
115	Polymorphisms in inflammatory cytokines and Fc ^î ³ receptors in childhood chronic immune thrombocytopenic purpura: a pilot study. British Journal of Haematology, 2001, 113, 596-599.	2.5	87
116	PEDIATRIC HEMATOLOGY AND ONCOLOGY AT THE UNIVERSITY CHILDREN'S HOSPITAL, BASEL, SWITZERLAND. Pediatric Hematology and Oncology, 2000, 17, 15-19.	0.8	0
117	Ethnicity and Environment May Affect the Phenotype of Immune Thrombocytopenic Purpura in Children. Pediatric Research, 2000, 48, 374-379.	2.3	21
118	Inv(11)(p13p15) and Myf-3(MyoD1) in a Malignant Extrarenal Rhabdoid Tumor of a Premature Newborn. Pediatric Research, 2000, 48, 463-467.	2.3	17
119	Successful local excision and long-term survival for invasive pulmonary aspergillosis during neutropenia after bone marrow transplantation. Journal of Thoracic and Cardiovascular Surgery, 2000, 119, 1286-1287.	0.8	10
120	CONTINUOUS INFUSION OF VON WILLEBRAND FACTOR AND FACTOR VIII AFTER ELECTIVE HEART SURGERY IN A 12-YEAR-OLD GIRL WITH VON WILLEBRAND DISEASE TYPE 3. Pediatric Hematology and Oncology, 1999, 16, 551-556.	0.8	7
121	Repeated peripheral stem cell mobilization in healthy donors: time-dependent changes in mobilization efficiency. British Journal of Haematology, 1999, 106, 152-158.	2.5	20
122	Familial clustering of Langerhans cell histiocytosis. British Journal of Haematology, 1999, 107, 883-888.	2.5	116
123	Management of children with acute and chronic immune thrombocytopenic purpura. Transfusion Science, 1998, 19, 261-268.	0.6	6
124	Chronic Immune Thrombocytopenic Purpura in Childhood. Seminars in Thrombosis and Hemostasis, 1998, 24, 549-553.	2.7	12
125	Molecular Diagnosis of Ewing Tumors. Diagnostic Molecular Pathology, 1998, 7, 29-35.	2.1	39
126	Immunologic aspects in the pathogenesis and treatment of immune thrombocytopenic purpura in children. Current Opinion in Pediatrics, 1997, 9, 35-40.	2.0	22

#	Article	IF	CITATIONS
127	Platelet and immune responses to oral cyclic dexamethasone therapy in childhood chronic immune thrombocytopenic purpura. Journal of Pediatrics, 1997, 130, 17-24.	1.8	69
128	Femtosecond dynamics of intramolecular charge transfer in 4-dimethylamino-4′-cyanostilbene in polar solvents. Chemical Physics Letters, 1996, 253, 69-76.	2.6	54
129	Platelet-Surface Glycoproteins in Healthy and Preeclamptic Mothers and Their Newborn Infants. Pediatric Research, 1996, 40, 876-880.	2.3	31
130	Platelet transfusion therapy in newborn infants. Transfusion Medicine Reviews, 1995, 9, 215-230.	2.0	51
131	Flow cytometric evaluation of platelet activation in blood collected into EDTA vs. Diatube-H, a sodium citrate solution supplemented with theophylline, adenosine, and dipyridamole. American Journal of Hematology, 1995, 50, 40-45.	4.1	52
132	All-Trans Retinoic Acid as an Alternative to Chemotherapy in the Treatment of Acute Promyelocyte Leukemia. Pediatric Hematology and Oncology, 1993, 10, 363-367.	0.8	1